WO2007030108A1 - Compositions de vitamine b12 - Google Patents

Compositions de vitamine b12 Download PDF

Info

Publication number
WO2007030108A1
WO2007030108A1 PCT/US2005/031628 US2005031628W WO2007030108A1 WO 2007030108 A1 WO2007030108 A1 WO 2007030108A1 US 2005031628 W US2005031628 W US 2005031628W WO 2007030108 A1 WO2007030108 A1 WO 2007030108A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
disease
subject
composition according
vitamin
Prior art date
Application number
PCT/US2005/031628
Other languages
English (en)
Inventor
Chad Brown
Original Assignee
Bebaas, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bebaas, Inc. filed Critical Bebaas, Inc.
Priority to PCT/US2005/031628 priority Critical patent/WO2007030108A1/fr
Priority to JP2008529966A priority patent/JP2009507071A/ja
Priority to EP05793864A priority patent/EP1933851A4/fr
Publication of WO2007030108A1 publication Critical patent/WO2007030108A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Definitions

  • the present invention provides improved vitamin B 12 compositions containing a mixture of vitamin B 12 analogues in effective amounts for enhanced delivery via the mucosal membranes, such as the mouth, nose, etc., to ameliorate any condition associated with vitamin B 12 deficiency in a patient.
  • Vitamin B 12 is synthesized by microbes, but not by humans or plants. Gastrointestinal absorption of vitamin B 12 , from food or supplements, depends on the presence of sufficient intrinsic factor and calcium ions. Adenosylcobalamin and methylcobalamin are the active forms of vitamin B 12 in humans. Vitamin B 12 deficiency may result from intrinsic factor deficiency (pernicious anemia), partial or total gastrectomy, or diseases of the distal ileum, intestinal problems and nerve damage, etc.
  • People or patients who have conditions that make them vulnerable to vitamin B 12 deficiency include those with Crohn's disease, multiple sclerosis, HIV/ AIDS, people who are 65 years or older, those with chronic intestinal inflammation, patients who have undergone intestinal surgery, patients whose food move too quickly throughout the intestine, people on strict vegetarian diets, people who drink alcohol excessively for longer than 2 weeks, people using acid reducing drugs for a long time period or patients that use chemotherapy drugs.
  • Vitamin B 12 has also been used in the treatment of IgE-mediated allergic diseases, such as allergic rhinitis and asthma. Oral ingested Vitamin B 12 is ineffective in the treatment of allergic disease, possibly due to liver metabolism.
  • Cyanocobalamin (Crystamine, Cyomin, Crysti 1000, Nascobal®) is the most widely sold analogue of Vitamin Bi 2 . Cyanocobalamin is available in injectable (subcutaneous or intramuscular) and oral forms and has the advantage of having a stable shelf life at standard temperature and pressure (STP). Cyanocobalamin — Nascobal® is also available as an intranasal gel and has been clinically shown to maintain adequate serum levels of Vitamin B 12 . The nasal gel can be self-administered through a simple nasal delivery system that avoids the discomfort of intramuscular injections of B 12 .
  • vitamin B 12 is very large, orally ingested cyanocobalamin is improperly digested and only small amounts of the vitamin get absorbed by the host.
  • the drawback of the injectable form is that it is invasive, expensive and inconvenient.
  • the present invention provides compositions and convenient methods for the delivery of vitamin B 12 compositions to patients with vitamin B 12 deficiencies.
  • the present invention provides a pharmaceutical composition comprising an effective amount of a mixture of methylcobalamine, hydroxycobalamin, and cyanocobalamin and a pharmaceutically acceptable carrier.
  • the present invention provides a pharmaceutical composition wherein said composition is in the form of a gel, a sublingual lozenge, a solution suitable for aerosolization for mucosal, nasal or pulmonary administration, a liposomal formulation, fine particles in a form suitable for aerosolization for mucosal or pulmonary administration or a tablet.
  • the pharmaceutical composition in the form of a gel is disposed within a capsule.
  • the present invention provides an apparatus for producing aerosolized doses of a composition in the form of fine particles, for mucosal or pulmonary administration, said apparatus comprising a means for introducing a preselected amount of said composition into a predetermined volume of a flowing propellent to produce an aerosolized quantity of said composition.
  • the present invention provides a method of treating or ameliorating a disease associated with vitamin B 12 deficiency, comprising administering to a subject suffering from or suspected of suffering from said disease an effective amount of any of the compositions described above.
  • the subject suffers from or is suspected to suffer from an anemia.
  • the anemia could be due to pernicious anemia, drug administration to said subject, Crohn's disease or burns.
  • the present invention provides a method of treating or ameliorating a disease or syndrome in a subject, comprising administering to said subject an effective amount of any of the compositions defined above, wherein said disease or syndrome is selected from the group consisting of cobalamin malabsorption, a neurological disorder, atrophic body gastritis, an autoimmune disorder, and symptoms associated with therapy with gastric acid inhibitors or biguanides.
  • the neurological disorder is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, and ataxia.
  • the present invention provides a method of treating an inflammatory disease in a subject, comprising administering to said subject an effective amount of any of the compositions defined above.
  • the inflammatory disease is joint inflammation or arthritis.
  • the present invention provides a method of reducing immunoglobulin E production in a subject comprising administering to said subject an effective amount of any of the compositions defined above.
  • the present invention provides a method of treating or ameliorating a disease associated with vitamin B 12 deficiency comprising using an apparatus for producing aerosolized doses of the composition described above, to administer an effective dose of said composition to a subject suffering from or suspected of suffering from said disease.
  • the present invention provides a kit comprising a pharmaceutical composition comprising an effective amount of a mixture of methylcobalamine, hydroxycobalamin, and cyanocobalamin and a pharmaceutically acceptable carrier.
  • active ingredients or compounds of the invention are meant types of cobalamins including, but not limited to, methylcobalamine, cyanocobalamin, , hydroxycobalamin, etc.
  • the active ingredients are used in different mixtures containing varying effective amounts of each active compound of the invention, which would be suitable for the treatment of different types of vitamin B 12 deficiencies.
  • mixture is meant a combination containing different types of active ingredients defined above, in effective amounts, useful for the treatment of vitamin B 12 deficiency.
  • an effective amount is meant that amount, which when administered, either alone or in a mixture, is sufficient to effect the treatment of a condition with vitamin B 12 deficiency.
  • inert ingredients is meant components like pharmaceutically acceptable carriers, adjuvant, diluents or excipients, etc., that must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions or a “formulation” as used herein is intended to encompass a product comprising the specified active ingredients in the specified amounts, as well as any product which results, directly or indirectly, from the combination of the specified active ingredients in the specified amounts.
  • Such term is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing any active compound of the present invention and a pharmaceutically acceptable carrier.
  • administering a should be understood to mean providing any active compound of the invention, in any formulation, to an individual in need of treatment.
  • vitamin B 12 is instilled in a carrier matrix, such as controlled release lozenges, troches, tablets, hard or soft capsules, syrups or elixirs, pressed pills, gel caps, chewing gum, gels such as metered gels that can be administered intranasally, nasal drops, creams, lotions, aqueous or oily suspensions, dispersible powders or granules, emulsions, sprays or aerosols using flowing propellents, like liposomal sprays, nasal sprays etc., douches and suppositories, transdermal patches etc., all for patient-friendly, self- administration of effective amounts of vitamin B 12 .
  • a carrier matrix such as controlled release lozenges, troches, tablets, hard or soft capsules, syrups or elixirs, pressed pills, gel caps, chewing gum, gels such as metered gels that can be administered intranasally, nasal drops, creams, lotions, aqueous or oily suspensions, dispers
  • the active ingredients of the invention are useful in a method for the prevention or treatment of vitamin B 12 disorders in certain combinations.
  • the weight ratio of the respective ingredients may be varied when necessary and will depend upon the effective dose of each ingredient or the effective dose of the combination of all the active ingredients in a formulation. Generally, an effective dose of each will be used.
  • the total cobalamin weight in a lozenge will generally be around 3mg and preferably contains at least three active ingredients in the composition.
  • a combination of active ingredients is used in the composition, for example, methylcobalamine: hydroxycobalamin: cyanocobalamin.
  • the ratios of the active ingredients of the invention are in the range of 1 : 1 :2 to 1 :1:10.
  • the amount of methylcobalamine, and hydroxycobalamin advantageously will generally range from 250-750 ⁇ g, while the range for cyanocobalamin will generally range from 1500- 2500 ⁇ g in a 3 mg cobalamin formulation.
  • Other combinations of active ingredients of the present invention are also possible as is understood in the art, and will generally be within the aforementioned range.
  • compositions described above also may be administered separately.
  • administration of one element may be prior to, concurrent to, or subsequent to the administration of other element(s).
  • compositions of the present invention may be used in combination with other drugs that are used in the treatment/prevention/suppression or amelioration of vitamin B 12 deficiencies or conditions.
  • Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present invention.
  • a composition of the present invention is used contemporaneously with one or more other drugs or herbal supplements, vitamin supplements, etc.
  • a pharmaceutical composition containing such other drugs in addition to the composition of the present invention is preferred.
  • the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to the compositions of the present invention.
  • the present invention provides a kit comprising a composition or formulation of the invention and instructions which comprise for storage, administration, dosing, disease state for which the formulation is useful, etc.
  • the present invention provides an article of manufacture comprising a composition or formulation of the invention and an apparatus to dispense or administer the formulation to a given patient, such as container for housing the compound, etc.
  • the subject compounds are useful in a method for the prevention or treatment of the following diseases, disorders and conditions.
  • the following diseases, disorders and conditions are related to Vitamin B 12 deficiency, and therefore may be treated, controlled or in some cases prevented, by treatment with the composition of this invention: (1) pernicious anemia, (2) ataxia, (3) autoimmune disorders, (4) patients receiving long term therapy with gastric acid inhibitors like biguanides, (5) patients with atrophic body gastritis, or have had partial or total gastrectomy, (6) anemia associated with chemotherapy treatment (for example, methotrexate, metformin, phenobarbital, phenytoin, etc.
  • chemotherapy treatment for example, methotrexate, metformin, phenobarbital, phenytoin, etc.
  • vitamin B 12 is instilled in a carrier matrix, such as controlled release lozenges, pills, troches, tablets, hard or soft capsules, syrups or elixirs, pressed pills, gel caps, chewing gum, gels such as metered gels that can be administered intranasally, creams, lotions, aqueous or oily suspensions, dispersible powders or granules, emulsions, sprays or aerosols using flowing propellants, like liposomal sprays, nasal drops, nasal sprays etc., douches and suppositories, transdermal patches etc., all for patient-friendly, self-administration of effective amounts of vitamin B 12 .
  • a carrier matrix such as controlled release lozenges, pills, troches, tablets, hard or soft capsules, syrups or elixirs, pressed pills, gel caps, chewing gum, gels such as metered gels that can be administered intranasally, creams, lotions, aqueous or oily suspensions, dis
  • the vitamin B 12 in formulations such as lozenges, troches, tablets, hard or soft capsules, gum etc. are preferably absorbed directly via the mucosa, such as buccal, nasal mucosa, into the blood stream before being subjected to digestion and degradation in the liver.
  • Preferred vitamin B 12 formulations include nasal gels, sublingual lozenges, nasal drops, nasal or pulmonary or other mucosal sprays, fast absorbing capsules or tablets, etc.
  • the vitamin B 12 formulations of the present invention may be administered, but are not limited to, oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, intranasal, transbuccal, mucosal, pulmonary, transdermal, liposomal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant
  • inhalation spray e.g., intranasal, transbuccal, mucosal, pulmonary, transdermal, liposomal, vaginal, rectal, sublingual, or topical routes of administration and
  • compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by methods well known in the art of pharmacy. Suitable methods are described in, for example, Remington, The Science and Practice of Pharmacy, ed. Gennaro et ah, 20th Ed. (2000), although the skilled artisan will recognize that other methods are known and are suitable for preparing the compositions of the present invention. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • compositions containing the active ingredient may also be in a form suitable for oral use, for example, as tablets.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin; or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Formulations are also useful as dry powders or granules. Dispersible, dry powders are useful for inhalation after aerosolization with a suitable dispersion device. Dry powder dispersion devices for medicaments are described in a number of patent documents.
  • U.S. Pat. No. 3,921,637 describes a manual pump with needles for piercing through a single capsule of powdered medicine. The use of multiple receptacle disks or strips of medication is described in EP 467172 (where a reciprocatable piercing mechanism is used to pierce through opposed surfaces of a blister pack); WO91/02558; WO93/09832; WO94/08522; U.S. Pat. Nos.
  • Dispersible powders and granules are also suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.
  • Additional excipients for example sweetening, flavoring and coloring agents, may also be present.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may sometimes be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution, hi addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • creams, gels including nasal gels, ointments, jellies, solutions or suspensions, mouth washes and gargles, etc., containing the compounds of the present invention are employed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions de vitamine B12 améliorées contenant un mélange d'analogues de vitamine B12 qui sont mieux absorbés dans la circulation sanguine d'un patient ayant une carence en vitamine B12, de préférence par l'intermédiaire de leurs membranes muqueuses, et concerne en outre des procédés d'administration commodes et économiques pour ces compositions, qui ne provoquent pas les désagréments associés aux injections sous-cutanées ou intramusculaires.
PCT/US2005/031628 2005-09-07 2005-09-07 Compositions de vitamine b12 WO2007030108A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/US2005/031628 WO2007030108A1 (fr) 2005-09-07 2005-09-07 Compositions de vitamine b12
JP2008529966A JP2009507071A (ja) 2005-09-07 2005-09-07 ビタミンｂ１２組成物
EP05793864A EP1933851A4 (fr) 2005-09-07 2005-09-07 Compositions de vitamine b12

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/031628 WO2007030108A1 (fr) 2005-09-07 2005-09-07 Compositions de vitamine b12

Publications (1)

Publication Number Publication Date
WO2007030108A1 true WO2007030108A1 (fr) 2007-03-15

Family

ID=37836137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031628 WO2007030108A1 (fr) 2005-09-07 2005-09-07 Compositions de vitamine b12

Country Status (3)

Country Link
EP (1) EP1933851A4 (fr)
JP (1) JP2009507071A (fr)
WO (1) WO2007030108A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609630B2 (en) 2005-09-07 2013-12-17 Bebaas, Inc. Vitamin B12 compositions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220066988A (ko) * 2017-03-24 2022-05-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 조성물 및 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428023A (en) * 1985-10-10 1995-06-27 Biotechnology Australia Pty. Ltd. Oral delivery of biologically active substances bound to vitamin B12 or analogues thereof
US6894033B2 (en) * 2001-06-11 2005-05-17 Transition Therapeutics Inc. Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL188625B1 (pl) * 1994-09-21 2005-03-31 Nektar Therapeutics Sposób wytwarzania aerozolu ze sproszkowanego leku, urządzenie do wytwarzania aerozolu ze sproszkowanego leku i pojemnik do przechowywania sproszkowanego leku
PT1128835E (pt) * 1998-12-28 2006-11-30 Cobalis Corp Tratamento com cianocobalamina (vitamina b12) em doença alérgica
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US20040162292A1 (en) * 2002-12-03 2004-08-19 Evenstad Kenneth L. Multivitamin formulations for promoting healthy collagen, and methods of their use
CA2575706A1 (fr) * 2004-08-02 2006-02-23 Bebaas, Inc. Compositions de vitamine b<sb>12</sb>

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428023A (en) * 1985-10-10 1995-06-27 Biotechnology Australia Pty. Ltd. Oral delivery of biologically active substances bound to vitamin B12 or analogues thereof
US6894033B2 (en) * 2001-06-11 2005-05-17 Transition Therapeutics Inc. Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1933851A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609630B2 (en) 2005-09-07 2013-12-17 Bebaas, Inc. Vitamin B12 compositions

Also Published As

Publication number Publication date
EP1933851A4 (fr) 2008-09-24
JP2009507071A (ja) 2009-02-19
EP1933851A1 (fr) 2008-06-25

Similar Documents

Publication Publication Date Title
US5543434A (en) Nasal administration of ketamine to manage pain
US8609630B2 (en) Vitamin B12 compositions
US20230081837A1 (en) Products of manufacture and methods for treating, ameliorating or preventing coronavirus infection
US20060024241A1 (en) Vitamin B12 compositions
US20080044455A1 (en) Tonsillitus Treatment
US20230001128A1 (en) Aerosolization systems, methods, and apparatuses
CN1092973C (zh) 乳香或乳香亲脂性提取物在制备用于治疗阿尔茨海默症的药物中的用途
US20070178141A1 (en) Vitamin B12 compositions
EP2799074A1 (fr) Chélate bis-glycinate de fer destiné à être utilisé dans le traitement oral de l&#39;anémie chez des patients atteints de la maladie c&#39;liaque
TW202241457A (zh) 用於預防病毒及微生物感染及其等之後遺症之藥物、治療組合、及方法
US20160000716A1 (en) Method of treating vitamin b12 deficiency
Tsutaoka et al. Superwarfarin and Glass Ingestion with Prolonged Coagulopathy Requiring High‐Dose Vitamin K1 Therapy
WO2007030108A1 (fr) Compositions de vitamine b12
KR20210131996A (ko) 과다복용 및 보상-기반 장애의 치료를 위한 조성물, 장치 및 방법
US20070053930A1 (en) Combination therapy for treatment of high cholesterol
US20220160619A1 (en) Effervescent Drug Formulations
JP5241127B2 (ja) 鎮痛用組成物
JP2000229853A (ja) 生理痛改善用組成物
Когай et al. Pharmacology: practical manual for students enrolled in the basic educational program of the specialty General medicine (bilingual program)
JPS58164516A (ja) 湿疹性皮膚疾患および薬疹治療剤
Powder Achrocort Cream
Sears et al. 2008 new drug approvals

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008529966

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005793864

Country of ref document: EP